Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease by Tang, Weihong et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic Associations for Activated Partial Thromboplastin Time
and Prothrombin Time, their Gene Expression Profiles, and Risk
of Coronary Artery Disease
Citation for published version:
Tang, W, Schwienbacher, C, Lopez, LM, Ben-Shlomo, Y, Oudot-Mellakh, T, Johnson, AD, Samani, NJ,
Basu, S, Gögele, M, Davies, G, Lowe, GDO, Tregouet, D-A, Tan, A, Pankow, JS, Tenesa, A, Levy, D,
Volpato, CB, Rumley, A, Gow, AJ, Minelli, C, Yarnell, JWG, Porteous, DJ, Starr, JM, Gallacher, J,
Boerwinkle, E, Visscher, PM, Pramstaller, PP, Cushman, M, Emilsson, V, Plump, AS, Matijevic, N,
Morange, P-E, Deary, IJ, Hicks, AA & Folsom, AR 2012, 'Genetic Associations for Activated Partial
Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery
Disease' American Journal of Human Genetics, vol 91, no. 1, pp. 152-162. DOI: 10.1016/j.ajhg.2012.05.009
Digital Object Identifier (DOI):
10.1016/j.ajhg.2012.05.009
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
American Journal of Human Genetics
Publisher Rights Statement:
Copyright © 2012 The American Society of Human Genetics. Published by Elsevier Ltd. Europe PubMed open
access link
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397273/[01/08/2013 12:29:14]
Am J Hum Genet. 2012 July 13; 91(1): 152–162.
doi:  10.1016/j.ajhg.2012.05.009
PMCID: PMC3397273
Genetic Associations for Activated Partial Thromboplastin Time and
Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery
Disease
Weihong Tang,  Christine Schwienbacher,  Lorna M. Lopez,  Yoav Ben-Shlomo,  Tiphaine Oudot-
Mellakh,  Andrew D. Johnson,  Nilesh J. Samani,  Saonli Basu,  Martin Gögele,  Gail Davies,
Gordon D.O. Lowe,  David-Alexandre Tregouet,  Adrian Tan,  James S. Pankow,  Albert Tenesa,  Daniel
Levy,  Claudia B. Volpato,  Ann Rumley,  Alan J. Gow,  Cosetta Minelli,  John W.G. Yarnell,  David J.
Porteous,  John M. Starr,  John Gallacher,  Eric Boerwinkle,  Peter M. Visscher,  Peter P.
Pramstaller,  Mary Cushman,  Valur Emilsson,  Andrew S. Plump,  Nena Matijevic,  Pierre-Emmanuel
Morange,  Ian J. Deary,  Andrew A. Hicks,  and Aaron R. Folsom
Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN 55454, USA
Center for Biomedicine, European Academy of Bozen/Bolzano (EURAC); affiliated institute of the University of Lübeck, Lübeck, Germany),
Viale Druso 1, 39100 Bolzano, Italy
Department of Experimental and Diagnostic Medicine, University of Ferrara, 44121 Ferrara, Italy
Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK
Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK
School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK
INSERM UMR_S 937; Institute of Cardiometabolism and Nutrition (ICAN); Université Pierre et Marie Curie (UPMC, Paris 6); 75013 Paris,
France
National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA 01702, USA
Center for Population Studies, National Heart, Lung and Blood Institute, Bethesda, MD 20824, USA
Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, MD 20824, USA
Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Leicester LE3 9QP, UK
National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester LE3 9QP, UK
Division of Biostatistics, University of Minnesota, Minneapolis, MN 55455, USA
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, UK
Institute of Genetics and Molecular Medicine, Medical Research Council (MRC) Human Genetics Unit, Edinburgh EH4 2XU, UK
The Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian EH25 9RG, UK
Epidemiology Research Group, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, UK
Medical Genetics Section, University of Edinburgh, Edinburgh EH4 2XU, UK
Alzheimer Scotland Dementia Research Centre, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK
Department of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK
Human Genetics Center and Human Genome Sequencing Center, University of Texas Health Science Center at Houston, Houston, TX
77030, USA
Queensland Statistical Genetics, Queensland Institute of Medical Research, Brisbane 4029, Australia
Department of Neurology, General Central Hospital, 39100 Bolzano, Italy
Department of Neurology, University of Lübeck, 23538 Lübeck, Germany
Departments of Medicine and Pathology, University of Vermont, Burlington, VT 05405, USA
Molecular Programming and Research Informatics, Merck & Co., Inc., Rahway, NJ 07065, USA
Department of Cardiovascular Disease, Merck Research Laboratory, Rahway, NJ 07065, USA
Hemostasis Laboratory, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
1,30, 2,3,30 4,5,30 6
7 8,9,10 11,12,31 13 2 5
14 7 13 1 15,16
9 2 14 4,5 2 17
4,18 4,19 20 21 22
2,23,24 25 26 27 28
29 4,5,30 2,30 1,30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397273/[01/08/2013 12:29:14]
INSERM, UMR_S 1062, Aix-Marseille Université, 13385 Marseille, France
Weihong Tang: tang0097@umn.edu
Corresponding author ; Email: tang0097@umn.edu
These authors contributed equally to this work
On behalf of the CARDIoGRAM Consortium; a full  list of CARDIoGRAM members can be found in the Supplemental Data
Received September 5, 2011; Revised April  10, 2012; Accepted May 5, 2012.
Copyright © 2012 The American Society of Human Genetics. Published by Elsevier Ltd. All right reserved.
Abstract
Activated partial thromboplastin time (aPTT) and prothrombin time (PT) are clinical tests commonly
used to screen for coagulation-factor deficiencies. One genome-wide association study (GWAS) has
been reported previously for aPTT, but no GWAS has been reported for PT. We conducted a GWAS and
meta-analysis to identify genetic loci for aPTT and PT. The GWAS for aPTT was conducted in 9,240
individuals of European ancestry from the Atherosclerosis Risk in Communities (ARIC) study, and the
GWAS for PT was conducted in 2,583 participants from the Genetic Study of Three Population
Microisolates in South Tyrol (MICROS) and the Lothian Birth Cohorts (LBC) of 1921 and 1936.
Replication was assessed in 1,041 to 3,467 individuals. For aPTT, previously reported associations with
KNG1, HRG, F11, F12, and ABO were confirmed. A second independent association in ABO was
identified and replicated (rs8176704, p = 4.26 × 10 ). Pooling the ARIC and replication data yielded
two additional loci in F5 (rs6028, p = 3.22 × 10 ) and AGBL1 (rs2469184, p = 3.61 × 10 ). For PT,
significant associations were identified and confirmed in F7 (rs561241, p = 3.71 × 10 ) and
PROCR/EDEM2 (rs2295888, p = 5.25 × 10 ). Assessment of existing gene expression and coronary
artery disease (CAD) databases identified associations of five of the GWAS loci with altered gene
expression and two with CAD. In summary, eight genetic loci that account for 29% of the variance in
aPTT and two loci that account for 14% of the variance in PT were detected and supported by
functional data.
Main Text
Activated partial thromboplastin time (aPTT) and prothrombin time (PT) are clinical tests commonly
used to screen for coagulation-factor deficiencies.1–3 aPTT measures the clotting time between the
activation of factor XII (FXII) and the formation of a fibrin clot; thus, aPTT reflects the integrity of the
intrinsic and common coagulation pathways.2,3 PT measures the clotting time from the activation of
FVII and reflects the integrity of the extrinsic and common coagulation pathways.2,3 Shorter aPTT is a
risk marker for incident and recurrent venous thromboembolism (VTE) in the general population,4,5
and activated coagulation is implicated in arterial thrombosis.6 An abnormal PT may reflect liver
damage, deficiencies in clotting factors and vitamin K, or the use of blood thinners.3
Family-based studies have yielded heritability estimates of 0.43 to 0.83 for aPTT and 0.50 to 0.53 for
PT, respectively,7,8 and shared genetic correlations have been observed between coagulation and
thrombosis.9 To date, one genome-wide association study (GWAS) of aPTT, based on 542,050
genotyped SNPs in 1,477 participants of the Lothian Birth Cohorts (LBC) of 1921 and 1936 (LBC1921,
LBC1936),10 has been reported. In that study, genome-wide significant associations were identified for
variants at F12 (MIM 610619), KNG1 (MIM 612358), and HRG (MIM 142640).10 No GWAS has been
reported to date for PT. We report a community-based GWAS and meta-analysis for aPTT and PT
among participants of European ancestry and assess the functional and clinical relevance of identified
loci.
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The study population for aPTT comprised five community-based cohorts and two samples of
individuals with VTE (Table 1). The community-based cohorts included the Atherosclerosis Risk in
Communities (ARIC) study (final sample size n = 9,240; USA),11 the Genetic Study of Three Population
Microisolates in South Tyrol (MICROS) (n = 1,215; Italy),12 LBC1921 (n = 471; UK), LBC1936 (n = 925;
UK),13 and the Caerphilly Prospective Study (CaPS) (n = 891; UK).14 We studied individuals with VTE
from two independent samples of the Marseille Thrombosis Association (MARTHA; France) study:
MARTHA08 (n = 649) and MARTHA10 (n = 392). Given that the sample size for ARIC is much larger
than that of the other cohorts, the ARIC cohort was analyzed as the discovery cohort and the others as
replication cohorts.
PT was represented with the international normalized ratio (INR), which standardizes the PT measure
across studies. Data for INR were available from MICROS (n = 1,218), LBC1921 (n = 443), and
LBC1936 (n = 922) (Table 1). All the three samples were analyzed as discovery cohorts. Data from
MARTHA08 (n = 612) and MARTHA10 (n = 374), which recorded only the Quick value (a PT ratio of
the coagulation time as a percentage of normal), were analyzed as replications. Each study was
approved by the institutional review board of the corresponding institutes, and participants gave
informed consent.
aPTT and PT were measured in plasma with the use of automated coagulometers and on the basis of
standard protocols specified in the individual studies. Tests were conducted on the same day as blood
collection or within a few weeks (after freezing). aPTT in seconds (s) was available in all the cohorts
except LBC1921, in which only the aPTT ratio was available. The aPTT ratio was calculated as the ratio
of the subject's aPTT to the reference value of the laboratory and correlates nearly perfectly (R  = 0.95)
with aPTT values in LBC1936. INR was calculated as (subject's PT / mean normal PT) , where ISI
(international sensitivity index) is a measure of the sensitivity of a particular PT reagent and is
determined by the manufacturers. Additional details on the coagulation measurements are provided in
Table S1 available online.
Each study independently performed assays for genome-wide SNPs, quality control, and imputation on
2.5 million autosomal SNPs identified in the HapMap II sample with European ancestry (CEU [Utah
residents with ancestry from northern and western Europe]). DNA samples were obtained from blood.
The SNP arrays used were Affymetrix 6.0 in ARIC, Illumina HumHap300v2 Infinium in MICROS,
Illumina Human 610_Quadv1 in both LBC cohorts, Illumina Human 610_Quad in MARTHA08, and
Illumina Human 660W_Quad in MARTHA10. Before imputation, SNPs were filtered on the basis of
sample and SNP call rates, Hardy-Weinberg equilibrium p values, and minor allele frequencies.
Imputation was performed with the use of MACH software15,16 in all cohorts for estimation of the
“allele dosage.” The accuracy of imputation was reflected by the ratio of observed to expected variance
(OEV) of the dosage statistic for each SNP. In CaPS, de novo replication genotyping was performed
with a fluorescence-based competitive allele-specific PCR system by KBioscience (Hoddesdon, UK).
Genotyping was successful in 22 out of 24 SNPs analyzed. Details are provided in Table S1. In addition,
the FV Leiden variant (rs6025, MIMs 188055 and 612309) and the top SNP for aPTT on chromosome
5 (rs2545801) were genotyped in ARIC with an Illumina assay as part of the Candidate gene
Association Resource (CARe) project. The CARe data for rs2545801 were analyzed for confirmation of
the GWAS results for this variant, which was imputed with borderline precision in ARIC (OEV = 0.3).
The association of aPTT or INR with genotyped or imputed SNPs was tested with the use of an additive
genetic model in accordance with a unified analysis plan. Outliers or users of anticoagulants were
excluded. Analysis was conducted with linear regression models for studies of unrelated individuals. A
score test17 was used for testing the genetic associations while accounting for familial correlations in
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MICROS, which is a population study that contains related individuals in extended families. All
analyses were adjusted for age, sex, and other cohort-specific covariates and were performed with
ProbABEL-GenABEL,18 Mach2QTL,15,16 or PLINK (Table S1).19
For aPTT, we performed an effective-sample-size-weighted meta-analysis to combine p values and the
direction of genetic effects from the replication (MICROS, LBC1921, LBC1936, and CaPS) and discovery
(ARIC) cohorts. The p value-based approach was chosen because of mixed aPTT and aPTT-ratio
measurements across cohorts. For INR, a fixed-effect, inverse-variance-weighted meta-analysis
approach was used to pool p values and β coefficients from MICROS, LBC1921, and LBC1936. The
genomic-control correction was applied to each study before the meta-analysis. The genomic-control
inflation factor λ was around 1 (0.98–1.03) for both aPTT and INR in all cohorts and in the meta-
analyses. The meta-analyses were conducted with the METAL package.20 The MARTHA data were not
pooled with the community-based cohorts because of the possibility of different allele frequencies,21
linkage disequilibria (LD), and effect sizes in individuals with VTE compared to the general population.
To examine the evidence for additional independent signals in the presence of several significant
associations at a given locus, we performed additional conditional analyses by adjusting for the top SNP
observed in the region until there were no significant residual signals detected. LD statistics (r ) were
estimated from combined data of the HapMap CEU and SeattleSNPs Programs for Genomic
Applications (PGA) European panel. Interaction was tested between top SNPs of identified genes that
have apparent biological effects (KNG1, HRG, F11 [MIM 264900], and F12) and was represented by a
cross-product term between dosages of two tested SNPs. Multiple testing was accounted for by
Bonferroni correction.
The aPTT GWAS findings are described in this and the next six paragraphs. As shown in Figures S1 and
S2 and Table S2, 331 SNPs in ARIC from six regions exceeded the genome-wide significance threshold
of p < 5 × 10 . These included one SNP within F5 (MIM 612309), 107 SNPs in KNG1/HRG, 28 SNPs
in CYP4V2 (MIM 608614) /KLKB1 (MIM 229000) /F11, 110 SNPs in F12, four SNPs in C6orf10, and
81 SNPs in ABO (MIM 110300). In the meta-analysis pooling data from ARIC, MICROS, LBC1936, and
LBC1921 (Figures S3 and S4), a locus at chromosome 15q25.3 (three SNPs, within ATP/GTP binding
protein-like 1, AGBL1) and another group of 29 SNPs within the F5 region emerged as statistically
significant. Associations of aPTT with lead SNPs at the seven regions are presented in Table 2, Tables
S3 and S4, and Figures S5–S14.
More specifically, we confirmed independent associations with aPTT for rs710446 in KNG1, rs9898 in
HRG, and rs2731672 in F12, previously reported in the LBC cohorts (r  = 0.93 between rs2731672 and
our top SNP, rs2545801).10 We also provided confirmation with genome-wide significance for the
previously reported association of the ABO O blood group with aPTT in candidate-gene studies (top
SNP: rs687621, r  = 0.67 with the O functional variant).22,23
At the CYP4V2/KLKB1/F11 region, conditional analysis in ARIC identified two sets of independent
signals led by two intronic variants in F11: rs2289252 (top SNP, p = 4.30 × 10 ) and rs1593 (p =
1.25 × 10 ). These two SNPs were in LD (r  = 0.09). After adjusting for rs2289252, rs1593 was still
associated with aPTT (p = 2.01 × 10 ). The first locus tagged by rs2289252 was identified as
suggestive by a pathway-based approach in the previously published GWAS for aPTT in LBC (top SNP:
rs4253399, p = 1.8 × 10 , r  = 0.79 with rs2289252).10 The second locus led by rs1593 has not
previously been associated with aPTT, and it explains an additional 0.33% of the variance in aPTT in
ARIC beyond what was explained by rs2289252 (Table S3).
The associations we identified for aPTT with F5, C6orf10, AGBL1, and a second independent locus in
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ABO have not been previously reported for aPTT. The two loci in F5, tagged by rs9332701 and rs6028,
reside in coding regions of F5 and are independent (r  = 0.015). In ARIC, adjustment for rs9332701
only minimally influenced the signal for rs6028 (p = 3.84 × 10  and 4.27 × 10  before and after
adjustment, respectively). Heterozygotes for rs9332701 have 25% lower plasma FV levels.24 The
associations between aPTT and the two F5 variants in this study were not due to their LD with the FV
Leiden variant (rs6025), because rs6025 was neither associated with aPTT (p = 0.54 for rs6025 in
ARIC) nor correlated with the two F5 variants (r  < 0.005). The second independent locus at the ABO
region for aPTT included 20 significant SNPs and emerged after additionally adjusting for the top SNP,
rs687621. The associations were led by rs4363269 and rs8176704. Of the 20 significant signals, only
rs8176704 is located within a gene (intronic to ABO, p = 0.02 and 4.26 × 10  before and after
adjustment for rs68762, respectively); it tags the ABO A2 variant (r  = 1), is in weak LD with rs687621
(r  = 0.20), and explains an additional 1.0% of the variance in aPTT beyond what is explained by
rs687621.
Among the six genome-wide significant associations for aPTT, identified in ARIC or the meta-analysis,
the top signal in F11 (rs2289252) and two independent ones in the ABO region (rs687621 and
rs8176704) were confirmed in the replication samples (Table 2). The associations for rs9332701 in F5,
rs1593 in F11, adjusted for rs2289252, and rs2050190 in C6orf10 were not significantly replicated (
Table 2), possibly due to limited replication data. The two associations that emerged only in the meta-
analysis (rs6028 in F5 and rs2469184 in AGBL1) were consistent across individual cohorts but require
additional replication (Table 2 and Tables S2–S4). Of note, AGBL1 and C6orf10 were not previously
known to affect coagulation.
In ARIC, we evaluated ten interactions for aPTT among the top SNPs in KNG1 (rs710446), HRG
(rs9898), F11 (rs2289252 and rs1593), and F12 (rs2545801). On the basis of a Bonferroni-adjusted
alpha of 0.005, the interactions for rs710446 × rs9898, rs710446 × rs1593, and rs710446 × rs2545801
were statistically significant (Table S5). The interactions of rs710446 with rs9898 or with rs2545801
offset the marginal effects of the aPTT-decreasing alleles (Figure S15).
In ARIC, the six loci in KNG1, HRG, F11, F12, and ABO, which were replicated, together explained
28.7% of the variation in aPTT, with 6.0% attributable to the genome-wide significant associations in
F11 (rs2289252) and ABO (rs687621 and rs8176704) that were not reported in the previous GWAS. A
genetic risk score was created by summing the product of the number of aPTT-increasing alleles and
the β coefficient from the meta-analysis for the lead SNPs in the six loci, with the genetic risk score
rescaled to 100%. The genetic risk score showed an accurate prediction of aPTT values (Figure 1). The
Pearson correlation was 0.53 (p < 0.0001), and the linear-regression coefficient ± SE was 1.00 ± 0.016
between the observed and predicted aPTT values. The mean aPTT ranged from 25.7 s in individuals in
the lowest risk-score category (risk score ≤ 15, n = 111) to 33.8 s in those in the highest risk-score
category (>72, n = 159). Each 11-unit increase in the genetic risk score corresponds to 1.21 s higher
aPTT, which corresponds to the mean aPTT difference between VTE cases and controls.5
For the PT-related analyses, the INR GWAS results are presented in Table 3, Table S6, and Figures
S16–S19. Two loci exceeded the genome-wide significance threshold of p < 5 × 10 : 24 SNPs near or
within F7 (MIM 613878) (top SNP: rs561241, near F7 5′, p = 3.71 × 10 ) and 40 SNPs near or within
EDEM2 (MIM 610302) and PROCR (MIM 600646) (top SNP: rs2295888, intronic to EDEM2, p =
5.25 × 10 ). Of note, rs867186, another top variant (p = 4.65 × 10 ), is a coding nonsynonymous
variant in the endothelial protein C receptor gene (PROCR or EPCR). The lead SNPs at the two loci
together account for 10%–14% of the variation in INR. The associations were significantly replicated in
MARTHA (Table 3).
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We next investigated pathways and networks by entering the genome-wide-significant hits in the
STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database.25 Two networks were
identified, characterizing mainly the intrinsic and extrinsic pathways for aPTT and PT, respectively.
Other members of the identified networks were tested further at the gene level with the program
VEGAS (Versatile Gene-based Association Study), which performs gene-based tests after taking into
account of LD among SNPs.26 In this pathway- and gene-based analysis (Figure S20), another gene,
PLG (plasminogen, MIM 173350), emerged as a suggestive locus for aPTT, and F5 emerged as a
suggestive locus for INR (p = 0.0048 for PLG and 0.017 for F5, significant threshold = 0.0033 for
aPTT genes and 0.006 for INR genes after Bonferroni correction). Plasmin, the activated form of
plasminogen, not only dissolves fibrin in blood clots, but also mediates the activation of the contact
coagulation system.27
We next conducted gene expression association analysis to focus on SNPs with p < 10  for aPTT (n =
1,124 SNPs) or INR (n = 340) from the meta-analysis. These SNPs were searched against a collected
database of expression quantitative trait locus (eQTL) results on the basis of blood-derived and related
organ tissues, including CD4+ lymphocytes,28 monocytes,29 adipose and blood samples,30,31 liver,31–
33 and brain tissues (V.E., unpublished data). eQTL results were judged significant based on p < 4 ×
10  and 1 × 10  for aPTT and INR, respectively, after accounting for multiple testing. Table 4
presents the smallest gene expression association p values for each relevant tissue at the corresponding
GWAS regions. When the top GWAS SNPs were not available in the expression databases, expression
SNPs (eSNPs) that correlated with the top GWAS SNPs at r  ≥ 0.8 were considered as strongly
supporting eSNPs. As shown in Table 4 and Tables S7 and S8, five of the GWAS loci (F5, F12, ABO, F7,
and EDEM2/PROCR) contained at least one strongly supporting eSNP in at least one tissue, with
strong support for F5, F12, F7, PROCR, and EIF6 (eukaryotic initiation translation factor 6, MIM
602912) as important genes.
We next assessed the clinical relevance of the top ten independent SNPs associated with aPTT or INR
using the CAD GWAS data from the Coronary Artery Disease Genome-wide Replication and Meta-
analysis (CARDIoGRAM) study, which comprises 22,233 cases of CAD and 64,762 controls of European
ancestry.34,35 The threshold for statistical significance was set at p < 0.005 for aPTT loci and p <
0.025 for INR after adjustment for multiple testing. As shown in Table S9, CAD was strongly and
significantly associated with the proxy SNP for the O group (rs687621: odds ratio [OR] [95%
confidence interval (CI)] = 1.06 [1.03–1.10] per one copy increase in the minor allele, p = 4.0 × 10 )
and with the top variants at the PROCR/EDEM2 locus (rs867186: OR [95% CI] = 0.93 [0.89–0.97], p =
0.002). The ABO-O association was consistent with previously published results in CARDIoGRAM.34
These results highlight that the coagulation pathways represent major molecular mechanisms through
which some of the recently identified CAD risk alleles34 may be operating.
In this and the next four paragraphs, we offer a discussion of our results. This study provides evidence
confirming the contributions of genetic factors in the CYP4V2/KLKB1/F11 region to normal variation of
aPTT. Multiple SNPs in CYP4V2, KLKB1, and F11 have been independently associated with deep vein
thrombosis (DVT)36,37, and the first top SNP for aPTT, rs2289252, was confirmed as a strong DVT
variant.37,38 Another SNP, rs2036914, was associated with DVT independent of rs2289252.37 We
noted that rs1593, the second top independent variant for aPTT, associated more strongly with
rs2036914 than with rs2289252 (r  = 0.17 versus 0.09). These observations, combined with the GWAS
data presented in this study, suggest that more than one locus at this region influences coagulation
function and the risk of DVT.
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We not only confirmed the previously reported positive association between the ABO-O blood group
and aPTT,22,23 but also identified a second independent locus represented by rs8176704, a perfect tag
for the A2 group. The genome-wide significant associations for the second locus emerged after
adjustment for the top SNP, rs687621, a tag for the O group. The adjustment substantially improved
the signal for rs8176704, due to the existence of negative confounding between the two variants. There
is a modest LD between the two variants (r  = 0.2), with the minor allele of rs8176704 residing on the
same ancestral haplotype block as the minor allele of rs687621 (Figure S21). These two alleles showed
opposite directions of association with aPTT and, therefore, counteracted the marginal association with
each other when the adjustment was not considered. ABO encodes a glycosyltransferase with three
main alleles: A, B, and O. The A and B glycosyltransferases transfer N-acetyl-D-galactosamine and D-
galactose to H antigen, respectively, whereas the O glycosyltransferase does not possess any enzymatic
function.39 The A2 subgroup is characterized by a single-base deletion near the carboxyl terminal,
resulting in a protein with little or no A-type transferase activity.40 The influence of the ABO blood
group on coagulation function has been postulated to be mediated through plasma clearance of von
Willebrand factor (vWF), i.e., quicker clearance of vWF in O and A2 groups.41 Both the O and A2
groups are associated with reduced risk of VTE,42 indicating that both loci for aPTT are clinically
relevant.
The significant genetic interactions of KNG1 with HRG and F12 have not been previously reported. In
the intrinsic or contact coagulation pathway, high-molecular-weight kininogen (HMWK), encoded by
KNG1, acts as a cofactor for activation of kallikrein and FXI and FXII.43 HRG encodes a histidine-rich
glycoprotein, which is located in the plasma and platelets. The physiological function of HRG is not well
understood, but it is known to interact with heparin, thrombospondin, and plasminogen.44 Human
cases with congenital deficiency of HRG manifested thrombophilia (MIM 613116).45,46 Mice deficient
in HRG showed enhanced blood coagulation and fibrinolysis.47 KNG1 and HRG are located
immediately adjacent to each other on chromosome 3. There is a high degree of structural similarity
between them,48 indicating the possibility of shared function.48 The interaction detected in our study
suggests that HRG may interact with the same receptors as HMWK in the intrinsic or contact
coagulation pathway.
SNPs in F7 were a major contributor to variation of the functional index of the extrinsic pathway,
explaining 8.6%–12.2% of variance in PT (INR). One of the top variants at this region, rs6046, results
in an arginine-glutamine (R353Q) substitution. It was associated with FVII antigen and activity in a
published GWAS.49 Interestingly, this variant explains more variance in INR than in FVII antigen and
activity,49 suggesting that additional mechanisms, such as the interaction of FVII with other
coagulation factors in the extrinsic pathway, may underlie the observed genetic associations.
Positive associations of the minor allele of rs867186 (PROCR S219G) with circulating levels of protein C
and soluble EPCR (sEPCR) have been reported consistently in candidate-gene50–52 and GWAS
studies.53 This variant explained 10%–13% of variation in protein C and 75% in sEPCR.51,53 The
association between PT and the variants at this locus may be mediated through the interaction of EPCR
with FVII, as the binding of activated FVII to EPCR has been observed.54,55 Our study has extended
the previously reported genetic associations with FVII antigen and activity49,52 to the global functional
assay of the extrinsic pathway. The association of rs867186 with CAD has been investigated in two
small-sized candidate-gene studies, which observed null or opposite directions of association compared
to ours.50,51 Our study, based on data from a larger CAD consortium, has greater statistical power. The
minor allele that was associated with decreased risk of CAD in our study was also associated with
increased protein C levels,51,53 consistent with the hypothesis of a protective effect of the protein C-
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activated protein C pathway on CAD risk.56 Interestingly, the rs867186/rs2295888 locus also showed
strong associations with the expression of the ITGB4BP/EIF6, which is involved in regulation of
translation in response to extracellular signals.57 As such, the gene expression data may point to a
novel mechanism by which this locus influences coagulation and CAD risk.
In summary, we identified and replicated genome-wide significant associations at KNG1, HRG, F11,
F12, and ABO for aPTT and at the F7 and PROCR/EDEM2 regions for PT. The loci identified in
previous studies and in this study together explained a substantial proportion of the variance in aPTT
and PT, which are important clinical tests. The underlying causal variants in KNG1, HRG, and F12 may
interact with each other in influencing coagulation and aPTT levels. This GWAS, together with gene
expression and clinical CAD data, improves our understanding of the role of biological mechanisms in
the regulation of hemostasis and may offer new approaches to the prevention and treatment of arterial
and venous thrombosis.
Acknowledgments
We warmly thank all staff and participants. The individual studies were supported by the National
Institutes of Health (NIH) or other funding sources. W.T. is partially supported by NIH grant R01-
HL095603. We would like to thank the University of Minnesota Supercomputing Institute for use of the
Blade and Calhoun supercomputers. Additional acknowledgments for each study and conflict-of-
interest disclosures are listed in the Supplemental Data.
Supplemental Data
Document S1. Supplemental Acknowledgments, Consortium Members, Figures S1–S21,
and Tables S1, S3–S5, and S9:
Document S2. Tables S2 and S6–S8:
Web Resources
The URLs for data presented herein are as follows:
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
GeneCards, http://www.genecards.org/
International HapMap Project, http://www.hapmap.org
KBioscience genotyping services, http://www.kbioscience.co.uk/
MACH 1.0 and Mach2QTL, http://www.sph.umich.edu/csg/abecasis/MACH/
METAL, http://www.sph.umich.edu/csg/abecasis/metal
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org
PLINK, http://pngu.mgh.harvard.edu/ purcell/plink
ProbABEL and GenABEL, http://www.genabel.org/packages
SeattleSNPs, http://pga.gs.washington.edu/
STRING database, http://string-db.org/
UCSC Human Genome Browser Gateway, http://genome.ucsc.edu/cgi-bin/hgGateway
VEGAS, http://gump.qimr.edu.au/VEGAS/
References
1. White G.C., 2nd The partial thromboplastin time: defining an era in coagulation. J. Thromb.
Haemost. 2003;1:2267–2270. [PubMed: 14629454]
Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397273/[01/08/2013 12:29:14]
2. Kitchen S., McCraw A., Echenagucia M. 2nd ed. World Federation of Hemophilia (WFH); Montreal:
2010. Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual.
3. Jacobs D.S. Lexi-Comp; Hudson, Ohio: 2001. Laboratory test handbook.
4. Hron G., Eichinger S., Weltermann A., Quehenberger P., Halbmayer W.M., Kyrle P.A. Prediction of
recurrent venous thromboembolism by the activated partial thromboplastin time. J. Thromb. Haemost.
2006;4:752–756. [PubMed: 16634742]
5. Zakai N.A., Ohira T., White R., Folsom A.R., Cushman M. Activated partial thromboplastin time and
risk of future venous thromboembolism. Am. J. Med. 2008;121:231–238. [PMCID: PMC2295205]
[PubMed: 18328308]
6. Owens A.P., 3rd, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb. Haemost.
2010;104:432–439. [PMCID: PMC3043984] [PubMed: 20539911]
7. Souto J.C., Almasy L., Borrell M., Garí M., Martínez E., Mateo J., Stone W.H., Blangero J.,
Fontcuberta J. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation.
2000;101:1546–1551. [PubMed: 10747348]
8. Warren D.M., Soria J.M., Souto J.C., Comuzzie A., Fontcuberta J., Blangero J., MacCluer J.W.,
Almasy L. Heritability of hemostasis phenotypes and their correlation with type 2 diabetes status in
Mexican Americans. Hum. Biol. 2005;77:1–15. [PubMed: 16114812]
9. Souto J.C., Almasy L., Borrell M., Blanco-Vaca F., Mateo J., Soria J.M., Coll I., Felices R., Stone W.,
Fontcuberta J., Blangero J. Genetic susceptibility to thrombosis and its relationship to physiological
risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am. J. Hum. Genet.
2000;67:1452–1459. [PMCID: PMC1287922] [PubMed: 11038326]
10. Houlihan L.M., Davies G., Tenesa A., Harris S.E., Luciano M., Gow A.J., McGhee K.A., Liewald D.C.,
Porteous D.J., Starr J.M. Common variants of large effect in F12, KNG1, and HRG are associated with
activated partial thromboplastin time. Am. J. Hum. Genet. 2010;86:626–631. [PMCID: PMC2850435]
[PubMed: 20303064]
11. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC
investigators. Am. J. Epidemiol. 1989;129:687–702.  [PubMed: 2646917]
12. Pattaro C., Marroni F., Riegler A., Mascalzoni D., Pichler I., Volpato C.B., Dal Cero U., De Grandi A.,
Egger C., Eisendle A. The genetic study of three population microisolates in South Tyrol (MICROS):
study design and epidemiological perspectives. BMC Med. Genet. 2007;8:29. [PMCID: PMC1913911]
[PubMed: 17550581]
13. Deary I.J., Gow A.J., Taylor M.D., Corley J., Brett C., Wilson V., Campbell H., Whalley L.J., Visscher
P.M., Porteous D.J., Starr J.M. The Lothian Birth Cohort 1936: a study to examine influences on
cognitive ageing from age 11 to age 70 and beyond. BMC Geriatr. 2007;7:28. [PMCID: PMC2222601]
[PubMed: 18053258]
14. Yarnell J.W., Sweetnam P.M., Rumley A., Lowe G.D. Lifestyle factors and coagulation activation
markers: the Caerphilly Study. Blood Coagul. Fibrinolysis. 2001;12:721–728. [PubMed: 11734674]
15. Li Y., Willer C., Sanna S., Abecasis G. Genotype imputation. Annu. Rev. Genomics Hum. Genet.
2009;10:387–406.  [PMCID: PMC2925172] [PubMed: 19715440]
16. Li Y., Willer C.J., Ding J., Scheet P., Abecasis G.R. MaCH: using sequence and genotype data to
Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397273/[01/08/2013 12:29:14]
estimate haplotypes and unobserved genotypes. Genet. Epidemiol. 2010;34:816–834.
[PMCID: PMC3175618] [PubMed: 21058334]
17. Chen W.M., Abecasis G.R. Family-based association tests for genomewide association scans. Am. J.
Hum. Genet. 2007;81:913–926. [PMCID: PMC2265659] [PubMed: 17924335]
18. Aulchenko Y.S., Ripke S., Isaacs A., van Duijn C.M. GenABEL: an R library for genome-wide
association analysis. Bioinformatics. 2007;23:1294–1296. [PubMed: 17384015]
19. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de
Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am. J. Hum. Genet. 2007;81:559–575. [PMCID: PMC1950838]
[PubMed: 17701901]
20. Willer C.J., Li Y., Abecasis G.R. METAL: fast and efficient meta-analysis of genomewide association
scans. Bioinformatics. 2010;26:2190–2191. [PMCID: PMC2922887] [PubMed: 20616382]
21. Morange P.E., Oudot-Mellakh T., Cohen W., Germain M., Saut N., Antoni G., Alessi M.C., Bertrand
M., Dupuy A.M., Letenneur L. KNG1 Ile581Thr and susceptibility to venous thrombosis. Blood.
2011;117:3692–3694. [PubMed: 21270443]
22. Fourel V., Gabastou J.M., Desroys du Roure F., Ehrhardt N., Robert A. Influence of age, sex and
ABO blood group on activated partial thromboplastin time. Haemostasis. 1993;23:321–326.
[PubMed: 8034238]
23. Souto J.C., Almasy L., Muñiz-Diaz E., Soria J.M., Borrell M., Bayén L., Mateo J., Madoz P., Stone
W., Blangero J., Fontcuberta J. Functional effects of the ABO locus polymorphism on plasma levels of
von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler. Thromb.
Vasc. Biol. 2000;20:2024–2028. [PubMed: 10938027]
24. Scanavini D., Girelli D., Lunghi B., Martinelli N., Legnani C., Pinotti M., Palareti G., Bernardi F.
Modulation of factor V levels in plasma by polymorphisms in the C2 domain. Arterioscler. Thromb.
Vasc. Biol. 2004;24:200–206.  [PubMed: 14656739]
25. Jensen L.J., Kuhn M., Stark M., Chaffron S., Creevey C., Muller J., Doerks T., Julien P., Roth A.,
Simonovic M. STRING 8—a global view on proteins and their functional interactions in 630 organisms.
Nucleic Acids Res. 2009;37(Database issue):D412–D416. [PMCID: PMC2686466] [PubMed: 18940858]
26. Liu J.Z., McRae A.F., Nyholt D.R., Medland S.E., Wray N.R., Brown K.M., Hayward N.K.,
Montgomery G.W., Visscher P.M., Martin N.G., Macgregor S., AMFS Investigators A versatile gene-
based test for genome-wide association studies. Am. J. Hum. Genet. 2010;87:139–145.
[PMCID: PMC2896770] [PubMed: 20598278]
27. Ewald G.A., Eisenberg P.R. Plasmin-mediated activation of contact system in response to
pharmacological thrombolysis. Circulation. 1995;91:28–36. [PubMed: 7805216]
28. Murphy A., Chu J.H., Xu M., Carey V.J., Lazarus R., Liu A., Szefler S.J., Strunk R., Demuth K.,
Castro M. Mapping of numerous disease-associated expression polymorphisms in primary peripheral
blood CD4+ lymphocytes. Hum. Mol. Genet. 2010;19:4745–4757. [PMCID: PMC2972694]
[PubMed: 20833654]
29. Zeller T., Wild P., Szymczak S., Rotival M., Schillert A., Castagne R., Maouche S., Germain M.,
Lackner K., Rossmann H. Genetics and beyond—the transcriptome of human monocytes and disease
Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397273/[01/08/2013 12:29:14]
susceptibility. PLoS ONE. 2010;5:e10693. [PMCID: PMC2872668] [PubMed: 20502693]
30. Fehrmann R.S., Jansen R.C., Veldink J.H., Westra H.J., Arends D., Bonder M.J., Fu J., Deelen P.,
Groen H.J., Smolonska A. Trans-eQTLs reveal that independent genetic variants associated with a
complex phenotype converge on intermediate genes, with a major role for the HLA. PLoS Genet.
2011;7:e1002197. [PMCID: PMC3150446] [PubMed: 21829388]
31. Greenawalt D.M., Dobrin R., Chudin E., Hatoum I.J., Suver C., Beaulaurier J., Zhang B., Castro V.,
Zhu J., Sieberts S.K. A survey of the genetics of stomach, liver, and adipose gene expression from a
morbidly obese cohort. Genome Res. 2011;21:1008–1016. [PMCID: PMC3129244] [PubMed: 21602305]
32. Schadt E.E., Molony C., Chudin E., Hao K., Yang X., Lum P.Y., Kasarskis A., Zhang B., Wang S.,
Suver C. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 2008;6:e107.
[PMCID: PMC2365981] [PubMed: 18462017]
33. Innocenti F., Cooper G.M., Stanaway I.B., Gamazon E.R., Smith J.D., Mirkov S., Ramirez J., Liu W.,
Lin Y.S., Moloney C. Identification, replication, and functional fine-mapping of expression quantitative
trait loci in primary human liver tissue. PLoS Genet. 2011;7:e1002078. [PMCID: PMC3102751]
[PubMed: 21637794]
34. Schunkert H., König I.R., Kathiresan S., Reilly M.P., Assimes T.L., Holm H., Preuss M., Stewart
A.F., Barbalic M., Gieger C., Cardiogenics. CARDIoGRAM Consortium Large-scale association analysis
identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 2011;43:333–338.
[PMCID: PMC3119261] [PubMed: 21378990]
35. Preuss M., König I.R., Thompson J.R., Erdmann J., Absher D., Assimes T.L., Blankenberg S.,
Boerwinkle E., Chen L., Cupples L.A., CARDIoGRAM Consortium Design of the Coronary ARtery
DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide
association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc
Genet. 2010;3:475–483. [PMCID: PMC3070269] [PubMed: 20923989]
36. Bezemer I.D., Bare L.A., Doggen C.J., Arellano A.R., Tong C., Rowland C.M., Catanese J., Young
B.A., Reitsma P.H., Devlin J.J., Rosendaal F.R. Gene variants associated with deep vein thrombosis.
JAMA. 2008;299:1306–1314. [PubMed: 18349091]
37. Li Y., Bezemer I.D., Rowland C.M., Tong C.H., Arellano A.R., Catanese J.J., Devlin J.J., Reitsma
P.H., Bare L.A., Rosendaal F.R. Genetic variants associated with deep vein thrombosis: the F11 locus. J.
Thromb. Haemost. 2009;7:1802–1808. [PubMed: 19583818]
38. Smith N.L., Hindorff L.A., Heckbert S.R., Lemaitre R.N., Marciante K.D., Rice K., Lumley T., Bis
J.C., Wiggins K.L., Rosendaal F.R., Psaty B.M. Association of genetic variations with nonfatal venous
thrombosis in postmenopausal women. JAMA. 2007;297:489–498. [PubMed: 17284699]
39. Greenwell P. Blood group antigens: molecules seeking a function? Glycoconj. J. 1997;14:159–173.
[PubMed: 9111133]
40. Hosoi E. Biological and clinical aspects of ABO blood group system. J. Med. Invest. 2008;55:174–
182. [PubMed: 18797129]
41. Morelli V.M., de Visser M.C., van Tilburg N.H., Vos H.L., Eikenboom J.C., Rosendaal F.R., Bertina
R.M. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand
factor with A and B antigens. Thromb. Haemost. 2007;97:534–541. [PubMed: 17393014]
Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397273/[01/08/2013 12:29:14]
42. Trégouët D.A., Heath S., Saut N., Biron-Andreani C., Schved J.F., Pernod G., Galan P., Drouet L.,
Zelenika D., Juhan-Vague I. Common susceptibility alleles are unlikely to contribute as strongly as the
FV and ABO loci to VTE risk: results from a GWAS approach. Blood. 2009;113:5298–5303.
[PubMed: 19278955]
43. Sainz I.M., Pixley R.A., Colman R.W. Fifty years of research on the plasma kallikrein-kinin system:
from protein structure and function to cell biology and in-vivo pathophysiology. Thromb. Haemost.
2007;98:77–83. [PubMed: 17597995]
44. Jones A.L., Hulett M.D., Parish C.R. Histidine-rich glycoprotein: A novel adaptor protein in plasma
that modulates the immune, vascular and coagulation systems. Immunol. Cell Biol. 2005;83:106–118.
[PubMed: 15748207]
45. Shigekiyo T., Yoshida H., Kanagawa Y., Satoh K., Wakabayashi S., Matsumoto T., Koide T.
Histidine-rich glycoprotein (HRG) Tokushima 2: novel HRG deficiency, molecular and cellular
characterization. Thromb. Haemost. 2000;84:675–679. [PubMed: 11057869]
46. Shigekiyo T., Yoshida H., Matsumoto K., Azuma H., Wakabayashi S., Saito S., Fujikawa K., Koide T.
HRG Tokushima: molecular and cellular characterization of histidine-rich glycoprotein (HRG)
deficiency. Blood. 1998;91:128–133.  [PubMed: 9414276]
47. Tsuchida-Straeten N., Ensslen S., Schäfer C., Wöltje M., Denecke B., Moser M., Gräber S.,
Wakabayashi S., Koide T., Jahnen-Dechent W. Enhanced blood coagulation and fibrinolysis in mice
lacking histidine-rich glycoprotein (HRG) J. Thromb. Haemost. 2005;3:865–872. [PubMed: 15869579]
48. Lee C., Bongcam-Rudloff E., Sollner C., Jahnen-Dechent W., Claesson-Welsh L. Type 3 cystatins;
fetuins, kininogen and histidine-rich glycoprotein. Front. Biosci. 2009;14:2911–2922.
[PubMed: 19273244]
49. Smith N.L., Chen M.H., Dehghan A., Strachan D.P., Basu S., Soranzo N., Hayward C., Rudan I.,
Sabater-Lleal M., Bis J.C., Wellcome Trust Case Control Consortium Novel associations of multiple
genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE
(Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation.
2010;121:1382–1392. [PMCID: PMC2861278] [PubMed: 20231535]
50. Ireland H., Konstantoulas C.J., Cooper J.A., Hawe E., Humphries S.E., Mather H., Goodall A.H.,
Hogwood J., Juhan-Vague I., Yudkin J.S. EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for
coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis. 2005;183:283–292.
[PubMed: 15921688]
51. Reiner A.P., Carty C.L., Jenny N.S., Nievergelt C., Cushman M., Stearns-Kurosawa D.J., Kurosawa
S., Kuller L.H., Lange L.A. PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant
phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health
Study. J. Thromb. Haemost. 2008;6:1625–1632. [PMCID: PMC2856703] [PubMed: 18680534]
52. Ireland H.A., Cooper J.A., Drenos F., Acharya J., Mitchell J.P., Bauer K.A., Morrissey J.H., Esnouf
M.P., Humphries S.E. FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by
EPCR Ser219Gly variant in healthy men. Arterioscler. Thromb. Vasc. Biol. 2009;29:1968–1974.
[PMCID: PMC2775706] [PubMed: 19696402]
53. Tang W., Basu S., Kong X., Pankow J.S., Aleksic N., Tan A., Cushman M., Boerwinkle E., Folsom
A.R. Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.
Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397273/[01/08/2013 12:29:14]
Blood. 2010;116:5032–5036. [PMCID: PMC3012596] [PubMed: 20802025]
54. Ghosh S., Pendurthi U.R., Steinoe A., Esmon C.T., Rao L.V. Endothelial cell protein C receptor acts
as a cellular receptor for factor VIIa on endothelium. J. Biol. Chem. 2007;282:11849–11857.
[PMCID: PMC2591933] [PubMed: 17327234]
55. López-Sagaseta J., Montes R., Puy C., Díez N., Fukudome K., Hermida J. Binding of factor VIIa to
the endothelial cell protein C receptor reduces its coagulant activity. J. Thromb. Haemost.
2007;5:1817–1824. [PubMed: 17723119]
56. Jackson C.J., Xue M. Activated protein C—an anticoagulant that does more than stop clots. Int. J.
Biochem. Cell Biol. 2008;40:2692–2697. [PubMed: 18249579]
57. Gandin V., Miluzio A., Barbieri A.M., Beugnet A., Kiyokawa H., Marchisio P.C., Biffo S. Eukaryotic
initiation factor 6 is rate-limiting in translation, growth and transformation. Nature. 2008;455:684–
688. [PMCID: PMC2753212] [PubMed: 18784653]
Figures and Tables
Figure 1
Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397273/[01/08/2013 12:29:14]
Cumulative Effect of the Lead SNPs in KNG1, HRG, F11, F12, and ABO on aPTT in ARIC
(A) Distribution of the genetic risk score (range: 0.24–85.1), and relation of risk-score categories to the mean aPTT (in
s). The histogram, with reference to the y axis on the left, represents the number of individuals in each risk-score
category. The black circles and error bars, with reference to the y axis on the right, indicate the mean aPTT ± SD (in s).
(B) Predicted versus observed aPTT values. The predicted aPTT values were calculated on the basis of the regression of
the observed aPTT on the genetic risk score.
Table 1
Description of Basic Study Participant Characteristics: Mean ± SD or Percentage unless Otherwise
Mentioned
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ARIC MICROS LBC1936 LBC1921 CaPS MARTHA08 MARTHA10
Total n 9,240 1,334 925 471 891 649 392
Age, in years 54.3 ± 5.7 44.7 ± 16.7 69.6 ± 0.84 79.1 ± 0.57 56.9 ± 4.3 44.4 ± 14.3 48.3 ± 16.1
Age range 45–64 9–94 68–71 78–81 48–67 1–90 7–85
% Female 52.9 57.2 49.4 59.6 0 75.8 63.3
BMI, in kg/m 27.0 ± 4.8 25.4 ± 4.8 27.8 ± 4.4 26.1 ± 4.2 26.7 ± 3.6 24.3 ± 4.4 25.8 ± 4.8
aPTT n 9,240 1,215 925 471 891 649 392
aPTT, in s 29.0 ± 2.9 26.6 ± 2.4 28.3 ± 2.6 0.90 ± 0.12 33.0 ± 2.8 31.3 ± 3.4 31.6 ± 3.2
Median aPTT 28.8 26.0 28.0 0.90 32.7 31.0 31.4
IQR aPTT 27.1–30.7 25.0–28.0 26.0–30.0 0.82–0.99 31.2–34.7 29.0–33.4 29.3–33.3
PT (INR) n NA 1,218 922 443 NA 612 374
PT (INR) NA 1.03 ± 0.12 0.96 ± 0.06 0.98 ± 0.08 NA 99.8 ± 13.5 101.4 ± 10.5
Median PT (INR) NA 1.02 1.00 0.98 NA 99.0 101.0
IQR PT (INR) NA 0.98–1.06 0.90–1.00 0.93–1.03 NA 91.0–107.0 94.2–108.0
BMI, body mass index; aPTT, activated partial thromboplastin time; PT, prothrombin time; INR,
international normalized ratio; IQR, interquartile range; NA, not available.
Overall n in the genome-wide association study of aPTT or INR after phenotype exclusions.
aPTT ratio.
The Quick value in %, which is in inverse relationship to INR.
Table 2
Association Parameters for Top SNP Associations in Activated Partial Thromboplastin Time Genome-
wide Association Study
Region Top SNP Position Gene/Var A1/A2/AF1 Imput
Beta/SE/Var% p Value/Direction
ARIC ARIC Replication MARTHA
n = 9,240
n =
9,240
n = 869–
3,467
n = 1,041
Achieving Genome-wide Significance in ARIC Alone
1q24.2 rs9332701 167751391 F5/cns A/G/0.95 - 0.54/0.10/0.30
3.70 ×
10 /+
0.62/+ NA
3q27 rs710446 187942621 KNG1/cns T/C/0.59
0.98–
1.00
−1.19/0.04/7.92
1.06 ×
10 /−
2.72 ×
10 /−
7.25 ×
10 /−
3q27 rs9898 187873321 HRG/cns C/T/0.65
0.87–
1.00
−1.01/0.04/5.41
1.65 ×
10 /−
5.03 × 10 /
−
2.58 ×
10 /−
4q35 rs2289252 187444375 F11/intr C/T/0.59
0.86–
0.97
−0.48/0.04/1.31
4.30 ×
10 /−
3.10 ×
10 /−
3.83 ×
10 /−
4q35 rs1593 187432545 F11/intr A/T/0.87
0.86–
0.90
0.54/0.06/0.77
1.25 ×
10 /+
0.005/+ 0.08/+
5q33-
rs2545801 176773945 F12/pro C/T/0.84
0.30–
1.55/0.05/10.64
4.13 × 3.49 × 6.20 ×
a
2
b
b
b
c c
c c
c c
a
b
c
a
c
−8
c
−185 −34 −22
d
−116
−6
−14
c
−30 −16 −5 e
d
−17
c g
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qter 0.89 10 /+ 10 /+ 10 /+
6p21.3 rs2050190 32447054 C6orf10/intr A/G/0.66
0.94–
0.99
−0.25/0.04/0.33
1.29 ×
10 /−
0.47/− 0.77/+
9q34.1-
.2
rs687621 135126886 ABO/intr A/G/0.65
0.99–
1.00
−0.82/0.04/3.52
3.64 ×
10 /−
7.25 ×
10 /−
5.18 ×
10 /−
9q34.1-
.2
rs8176704 135125373 ABO/intr G/A/0.93
0.90–
1.00
0.89/0.09/1.04
4.26 ×
10 /+
1.19 ×
10 /+
0.002/+
Achieving Genome-wide Significance in Meta-analysis of ARIC, MICROS, LBC1936, and LBC1921
1q24.2 rs6028 167818306 F5/cs T/C/0.69
0.97–
0.99
0.23/0.04/0.25
3.84 ×
10 /+
0.001/+ 0.59/+
15q25.3 rs2469184 84992981 AGBL1/intr G/A/0.55
0.99–
1.00
0.16/0.04/0.15
8.19 ×
10 /+
8.87 ×
10 /+
0.35/+
Beta, change in activated partial thromboplastin time (in s) per copy of the A2 allele (minor allele);
Var%, percentage of variance explained; Direction (+ or −), direction of association associated with the
minor allele; Var, variant of the top SNP; A1, allele 1 (major allele); A2, allele 2 (minor allele); Imput,
ratio of observed to expected variance as a measure of imputation quality (range presented here, 1 for
genotyped SNPs); AF1, allele frequency for A1; cns, coding nonsynonymous; NA, not available; PGWA,
previously published genome-wide association study (GWAS) in Lothian Birth Cohorts (LBC); intr,
intron; pro, promoter region; PCGS, previously published candidate-gene studies; cs, coding
synonymous.
n for replication: 869 is the n for rs9332701 that was only available in CaPS; n range for the other
SNPs is 2,252–3,467.
Based on meta-analysis of MARTHA08 and MARTHA10.
Top SNP in that region if there is more than one independent SNP.
Second independent SNP, p value after adjusting for the top SNP of the region in ARIC: 9.95 × 10
for rs9898, 2.01 × 10  for rs1593, and 4.27 × 10  for rs6028.
Result for proxy rs925451 (r  = 0.81 with rs2289252).
0.30 is the imputation quality score (OEV) in ARIC GWAS, OEV > 0.84 in the other cohorts.
Based on the results of ARIC genotyped data from the Candidate gene Association Resource (CARe)
project.
p value < 10  based on the ARIC genotype data from the CARe project.
Results are after additionally adjusting for rs687621 in all cohorts.
Table 3
p Values and Association Parameters for Top SNPs in Genome-wide Association Study for Prothrombin
Time by INR
Region Top SNP Position Gene/Var A1/A2/AF1
MICROS (n = 1,218) LBC1936 (n = 922) LBC    
Beta/SE/Var% p Beta/SE/Var% p Beta/
f −60 h −63 −11
−8
c
−81 −30 −10
d,i
−24 −5
d
−7
−5 −6
a
b
c
d −92
−8 −6
e 2
f
g
h −150
i
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13q34 rs561241 112808035 F7/near 5′ T/C/0.71 0.035/0.003/11.76
7.80 ×
10
0.040/0.004/8.78
2.75 ×
10
0.059/0
13q34 rs6046 112821160 F7/cns G/A/0.71 0.035/0.003/11.74
7.55 ×
10
0.040/0.005/8.61
4.89 ×
10
0.060/0
20q11.2 rs2295888 33186524 EDEM2/intr A/G/0.85 −0.020/0.004/2.53
5.87 ×
10
−0.018/0.005/1.60
7.77 ×
10
−0.027/
20q11.2 rs867186 33228215 PROCR/cns A/G/0.84 −0.020/0.004/2.50
9.98 ×
10
−0.017/0.005/1.38
2.44 ×
10
−0.024/
Var, variant of the top SNP; A1, allele 1 (major allele); A2, allele 2 (minor allele); AF1, allele frequency
for A1; Beta, change in international normalized ratio (INR) per copy of the A2 allele (minor allele);
Var%, percentage of variance explained; cns, coding nonsynonymous; intr, intron.
Based on meta-analysis of MARTHA08 and MARTHA10.
The Quick value, which is in inverse relationship to INR, was used in MARTHA.
SNPs labeled with similar symbols are in high linkage disequilibrium with each other. Imputation
quality scores ≥ 0.97 for all SNPs.
Table 4
Selected Top Gene Expression Associations Related to Loci for aPTT or INR
eSNP Region Tissue Genes Nearby
p Value
Expression/n
Transcript
p
Value
GWAS
r  to
Top
GWAS
SNP
Top
GWAS
SNP
aPTT
rs1894702 1q24.2
CD4+
lymphocytes28
F5;SELP
7.59 ×
10 /200
F5
8.11 ×
10
0.92 rs6028
rs7542088 monocytes29 F5;SELP
4.74 ×
10 /1,490
F5
9.37 ×
10
0.96 rs6028
rs3917854 whole-blood30 F5;SELP
3.90 ×
10 /1,469
F5
3.05 ×
10
0.96 rs6028
rs2731672 5q33 liver31
F12;GRK6; SLC34A1;
PRR7; RGS14;DBN1
6.13 ×
10 /607
F12
2.43 ×
10
0.93 rs2545801
liver32
1.16 ×
10 /472
F12
liver33
<1.00 ×
10 /206
F12
liver33 1.52 × 10 /60 F12
rs505922 9q34.2
CD4+
lymphocytes28
ABO;SURF6;MED22
2.69 ×
10 /200
ABO
1.04 ×
10
0.97 rs687621
rs2437792 15q25.3 CB AGBL1
5.34 ×
10 /496
AA620749
2.66 ×
10
0.87 rs2469184
c
−27 −19
c
−27 −19
d
−8 −5
d
−8 −4
a
b
c,d
a
2
−17 −9
−14 −9
−50 −8
−53 −34
−23
−16
−6
−5 −99
b
−5
c
−7
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INR
rs7981123 13q34 liver33 F7; MCF2L; F10
2.78 ×
10 /266
F7
7.24 ×
10
0.82 rs561241
liver33
4.88 ×
10 /206
F7
liver33
9.62 ×
10 /60
F7
rs488703
omental
adipose31
F7; MCF2L; F10
4.77 ×
10 /848
F7
1.23 ×
10
0.88 rs561241
rs10665
subcutaneous
adipose31
F7; MCF2L; F10
2.07 ×
10 /701
F7
6.45 ×
10
0.92 rs561241
DLPFC
1.82 ×
10 /583
F7
VC
1.33 ×
10 /409
F7
rs11906318 20q11.2 liver31 EDEM2;PROCR
3.20 ×
10 /607
PROCR
7.27 ×
10
1.00 rs2295888
rs11907010
omental
adipose31
EDEM2;PROCR
5.62 ×
10 /848
PROCR
1.03 ×
10
1.00 rs2295888
rs8119351 whole-blood30 EDEM2;PROCR
2.60 ×
10 /1,469
EIF6
1.19 ×
10
1.00 rs2295888
rs6060244 monocytes29 EDEM2;TRPC4AP
5.26 ×
10 /1,490
EIF6
7.02 ×
10
0.82 rs2295888
eSNP, expression SNP; GWAS, genome-wide association study; aPTT, activated partial thromboplastin
time; INR, international normalized ratio; CB, cerebellum; DLPFC, dorsolateral prefrontal cortex; VC,
visual cortex; EIF6, ITGB4BP.
“Nearby” is defined by 60,000 bp from gene boundaries; the genes are ordered by distance to the
eSNP; the gene in which the top eSNP is located is in bold font
V.E., unpublished data.
AA620749 maps to unspliced and spliced expressed sequence tags that are 25–60 kb 5′ of AGBL1.
rs7981123 is positioned at −350 nt from the F7 transcription start site and is within regulatory
elements based on alignment of ENCODE histone, DNase I hypersensitivity, and ChIP-sequencing data;
in dbSNP, rs7981123 has merged into rs510335.
Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human
Genetics
d
−10 −56
−10
−3
−10 −55
−6 −53
b
−7
b
−7
−20 −13
−18 −12
−46 −12
−24 −12
a
b
c
d
